← Who reports today · Health Care
TECH · Q4 FY2026
Archived report (Q4 FY2026). Latest deep dive →
Net earnings
$54.6M
Net sales
$321M
up 1.3% y/y
Operating income
$74.3M
Gross margin
$211M
up 6.3% y/y
The quarter in brief
Revenue grew 1.3% y/y to $321M, operating margin 23.1% vs 7.5%, net income $55M.
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net sales | $321 · +1.3% |
| Cost of sales | $110 · −7.1% |
| Gross margin | $211 · +6.3% · 65.8% margin |
| Selling, general and administrative | $113 · −42.4% |
| Research and development | $23.9 · −8.0% |
| Operating income | $74.3 · vs −$23.9 · 23.1% margin |
| Other income (expense) | $3.6 · vs $1 |
| Earnings before income taxes | $70.7 · vs −$22.9 |
| Income taxes | $16.1 · vs −$5.2 · 22.7% effective rate |
| Net earnings | $54.6 · vs −$17.7 · $0.35/sh · 17.0% margin |
Verdict: revenue grew 1.3% y/y to $321M, operating margin 23.1% vs 7.5%, net income $55M.
Bio-Techne agreed to be acquired by Merck KGaA for $73 per share in cash, an enterprise value of approximately $11.3 billion.
Source and notation
Source: Bio-Techne press release, 8-K EX-99.1 of 08/12/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: TECH, Q4 FY2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “TECH Q4 FY2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/tech/q4-fy2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/tech/q4-fy2026"><img src="https://whoreportstoday.com/t/tech/q4-fy2026/sankey.png" alt="TECH Q4 FY2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/tech/q4-fy2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/tech/q4-fy2026/sankey.png
<a href="https://whoreportstoday.com/t/tech/q4-fy2026">TECH Q4 FY2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Organic revenue rose 3% (1% as reported) to $321.2 million.
- Gross margin was 65.8% vs 62.7% a year earlier.
- Operating income was $74M, a 23.1% margin vs 7.5% a year earlier.
- The effective tax rate was 22.7% vs 22.7% a year earlier.
- Diluted EPS was $0.35 vs −$0.11 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
TECH — a life science tools company that develops and sells research reagents, protein analysis instruments, diagnostic controls and assays, and tissue-based spatial biology tools to researchers, drug developers and clinical labs.
It makes money in two segments: Protein Sciences and Diagnostics and Spatial Biology. · Source: annual report (Form 10-K, SEC)
More reports: TMO · Q3 2026 · UHS · Q3 2026 · UNH · Q3 2026 · VEEV · Q2 FY2027 · VRTX · Q3 2026 · VTRS · Q3 2026 · WAT · Q3 2026 · WST · Q3 2026 · ZBH · Q3 2026 · ZTS · Q3 2026 · all reports